# HSEF v5.3 review: Mitochondrial Dysfunction Hypothesis

> Sources: 70 primary reports; claims: 77; verified: 77; unverified: 0. Verification is bounded attribution. Access: 6 partial-body and 64 complete abstract/status examinations. Literature cutoff: 2026-10-07; source examination UTC date: 2026-10-07. No complete-paper audit or blinded calibration claimed.
> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 8 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Mitochondrial impairment can cause or amplify neuronal injury, but it is not established as the common initiating apex of sporadic neurodegeneration.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Γ — Mechanistically plausible, partial system support | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** In baseline genotype-, reserve- and protein-state-defined aged cohorts or validated natural-instrument cohorts, selectively preserve the implicated mitochondrial process before protein pathology, with matched protein-directed perturbation and mechanistic rescue. Follow incident disease, cell fate and function. Predefine disease-specific boundaries rather than pooling genetic HD with sporadic syndromes.

**Belief versus evidence:** Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast.

**Best-supported rival:** Multi-hit convergent loop. Measure baseline mitochondrial reserve and protein pathology before onset, then selectively perturb each direction. The leading multi-hit model predicts interactions; the reserve-only rival predicts injury from reserve regardless of upstream protein state.

## COMPETING MECHANISTIC MODELS

**Rank 1: Multi-hit convergent loop (Ε).** Genotype, proteinopathy, organelle quality control and inflammation converge on conditional metabolic vulnerability. Parkin/POLG interaction, protein-led import disruption, NCLX/USP30 rescue and variable PD complex-I subtypes support bounded reciprocal contribution. A flexible loop is not an independently proved universal explanation; prospective baseline predictions are still required.

**Rank 2: Selective vulnerability and permissive threshold (Ε).** Mitochondrial reserve and compartmental demand determine injury after defined stresses. Ndufs2 functional compensation, mtDNA-copy maintenance and young-mutator resistance distinguish reserve from inevitable cell death. Reserve biomarkers do not uniquely predict human onset or exclude protein-mediated injury.

**Rank 3: Proteinopathy-first amplification (Ε).** Pathogenic proteins initiate organelle disruption and mitochondrial changes amplify pathology. HTT repression, alpha-synuclein/TOM20 and SOD1/VDAC place proteins upstream in defined models. Mitochondrial lesions can also generate protein pathology; this is not the sole route to every sporadic case.

**Rank 4: Mitochondrial-first cascade (Γ).** Ordinary age-related mitochondrial failure initiates the common proteinopathies. Cell-transfer and mitochondrial genetic lesions supply coherent mechanistic support. Temporal human primacy and universal necessity are absent; physiological compensation and genetic HD contradict an unqualified common apex.

**Rank 5: Oxidative damage primacy (Γ).** ROS injury is the decisive common initiator rather than one downstream mediator. Redox perturbations and restricted edaravone clinical efficacy support relevance. Antioxidant interventions are nonspecific, and neither initiation nor adequate-target universal failure is established.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Age-related mitochondrial bioenergetic failure is a primary upstream causal driver of neurodegeneration, initiating rather than following proteinopathies in sporadic Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.

Use the index mitochondrial-first claim. Score forced lesions, HD biogenesis and PD mtDNA separately; SC5 gates the broad etiological-apex inference. Human treatment results are a separate application rather than an obligatory antioxidant clause.

Selection: public-interest rank 28 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

### Evidence and causal interpretation

TFAM disruption in MitoPark, adult conditional Parkin/PARIS loss and respiratory-genome editing demonstrate that mitochondrial insults can be causal in models. Original PARIS Results distinguish adult loss from germline compensation and verify TH plus Nissl degeneration and PARIS knockdown attenuation. Distinct endogenous instruments support SC2 Ζ without claiming normal ageing or human common primacy (PMID17227870, PMID21376232, PMID40069360).

Original Ndufs2 Results reveal a Warburg-like switch: ATP production becomes glycolytic and mitochondria consume imported ATP to retain potential. Dopamine release and TH decline while retrograde cell labelling and somatic integrity remain. This is powerful functional causality but cannot be called early neuronal death. Original Parkin/POLG Results instead use Nissl counts to confirm aged double-mutant death; neither single lesion does so, young mice are spared, and total mtDNA mutation burden is unchanged by Parkin loss (PMID34732887, PMID26182419).

Age-related mtDNA deletions coincide with respiratory deficits, but healthy aged neurons increase copy number and maintain wild-type genomes. PD can fail this compensation and has heterogeneous complex-I patterns. Single-cell associations, bulk point-variant nulls and forced point-mutator models do not together supply deletion-selective sporadic neuronal-fate causality (PMID16604072, PMID16604074, PMID27874000, PMID38684731, PMID28153046).

CHCHD2 loss preserves neurons/OXPHOS even with CHCHD10 deletion, whereas the pathogenic T61I knock-in causes age-dependent phenotypes. PINK1 human genetics and infection-conditioned knockout effects implicate multiple quality-control and immune functions. A mitochondrial-associated gene is not automatically a selective respiration instrument (PMID34791217, PMID36322611, PMID25226871, PMID31316206).

Alpha-synuclein inhibits TOM20 import and seeded pathology disrupts mitochondrial ATP. USP30 loss/inhibition and farnesol can protect induced neuronal/motor phenotypes. These support a modifiable organelle contribution downstream of experimentally imposed proteins; they do not identify spontaneous mitochondrial-first onset (PMID27280685, PMID39379975, PMID37957154, PMID34321320).

HTT represses PGC-1alpha; endogenous PGC-1alpha deletion worsens striatal degeneration and biogenesis interventions preserve model phenotypes. This supports contextual causal contribution. Huntington disease is inherited from expanded HTT, so the registered sporadic-HD wording cannot be defended as written. Original HD iPSC Results show lowered glycolytic capacity with largely retained respiratory reserve; late-metabolite rescue of ATP in human cells and viability in transfected mouse neurons are separate experiments. Isolated-respiration and import-localization counterexamples remain in the corpus (PMID17018277, PMID27008868, PMID30768179, PMID27131346, PMID32821928).

AD cybrid transfer can generate respiratory and A-beta/tau abnormalities, but HeLa cybrids from patient platelets or brain retain respiration. MCI is not demonstrably pre-proteinopathy. Shared rho-zero/transformed-cell preparations and divergent nuclear backgrounds prevent cellular transfer from establishing ordinary human initiation (PMID9339668, PMID10939564, PMID22746213, PMID10051601, PMID40596736).

Original NCLX Results verify neuronal deletion accelerates familial-transgene AD pathology and cognition, with activity controls. Regulated rescue begins after doxycycline withdrawal at four weeks, approximately doubles NCLX and prevents later decline; it is not demonstrated reversal after established dementia. NCLX loss alone and neuronal MCU deletion add causal calcium-pathway evidence. ApoE4/lysosomal and TREM1/myeloid pathways demonstrate additional upstream contexts (PMID31467276, PMID36936788, PMID42174122, PMID37777962, PMID38539014).

ALS pore evidence is internally informative. Early CypD work reports sex-dependent survival benefit, but a later three-SOD1-mutant study shows improved calcium buffering, ATP and soma survival without preventing denervation, progression or fatal paralysis. Protein-led VDAC and TDP-43/mtDNA-STING routes coexist with respiratory complex-IV sufficiency. A pathological mediator can preserve one compartment without controlling organismal disease (PMID19272377, PMID23486940, PMID20797535, PMID33031745, PMID40069360).

Clinical translation remains mechanism-specific. EMPOWER, olesoxime, CoQ10 and creatine regimens fail their major endpoints; isradipine explicitly permits insufficient target engagement. Restricted early-ALS edaravone benefit is real clinical evidence but does not isolate mitochondrial restoration. The German long-term cohort is observational, not a randomized replication. Null drugs are not a universal adequately-engaged mechanistic falsification (PMID24067398, PMID24447620, PMID24664227, PMID25668262, PMID32227247, PMID28522181, PMID35006266).

Original UDCA Methods designate safety as primary and state secondary/exploratory comparisons are unpowered and unadjusted for multiplicity. Results randomize 31, with 25 MRS participants and a smaller pandemic-limited gait subset. Midbrain energetics change and gait has a small signal, while UPDRS contrasts remain null. NADPARK raises brain NAD variably; NR-SAFE clinical changes covary with levodopa timing. These establish feasibility or metabolic engagement, not confirmed disease modification (PMID37246815, PMID35235774, PMID38016950).

Consensus broad retrieval supplied useful bidirectional hypotheses and gap leads, but its meter and all-therapies-engaged framing were not accepted. Targeted Pro reached its tool limit, recovering HD glycolytic Results while lacking four focal originals and citing an irrelevant alpha9 knockout. Original HD sections confirm the narrow indexed check. Six original-body examinations were recovered independently from NCBI PMC; failed MitoPark/Parone access earns no body credit. SciSpace independently led to the same HD glycolytic paper, resolved by DOI/PMID and deduplicated; service leads do not pad the 70-primary corpus.

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

<!-- consensus-consistency-2026-10-09 -->
### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/hsef_v53_popularity_ranks_26_30_2026-10-07/mitochondrial-cascade/consensus/broad-browser-snapshot.txt`
- `deliverables/hsef_v53_popularity_ranks_26_30_2026-10-07/mitochondrial-cascade/consensus/query-ledger.json`
- `deliverables/hsef_v53_popularity_ranks_26_30_2026-10-07/mitochondrial-cascade/consensus/reconciliation.md`
- `deliverables/hsef_v53_popularity_ranks_26_30_2026-10-07/mitochondrial-cascade/consensus/targeted-browser-snapshot.txt`

The located artifacts do not state a reliable source-comparison count. No count is inferred.

No earlier adversarial approval exists for this case; this provenance supplement is not a new independent or blinded adjudication. No score or confidence change is made by this reconciliation.
<!-- end-consensus-consistency -->


### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Mitochondrial deficits are present in neurodegenerative tissue. | AD, PD, HD and ALS tissue | Β | Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation. |
| SC2 Loss of mitochondrial function causes progressive neurodegeneration in vivo. | prespecified neuronal genetic lesions and toxins | Ζ | Tfam disruption, conditional adult Parkin/PARIS loss with Nissl-confirmed degeneration, combined POLG/Parkin stress and rat complex-IV editing provide distinct endogenous routes to disease-relevant injury. Model-level mitochondrial sufficiency reaches Ζ as a set. Ndufs2 primarily produces dysfunction with somatic survival and is not falsely counted as death. Contradictory pore effects and lesion severity block a uniform Η trajectory claim; sporadic human primacy is a separate subclaim. |
| SC3 Mitochondrial biogenesis supports striatal survival in HD models. | defined HD and PGC-1α settings | Ε | Endogenous PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice and matched gain-of-function/PPAR approaches preserve phenotypes. This is genuine context-dependent biogenesis contribution (Ε), despite pleiotropy. Mutant HTT is upstream; donor-cell glycolytic and isolated-respiration counterexamples limit generalization and exclusive bioenergetic explanation. |
| SC4 Somatic mtDNA deletion burden drives selective neuronal loss in sporadic PD. | age-related substantia nigra mtDNA burden | Γ | Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy. |
| SC5 Bioenergetic failure is the upstream etiological apex across sporadic neurodegeneration. | disease classes specified before outcomes | Γ | Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality. |
| SC6 Restoring mitochondrial function changes human disease trajectory. | human disease-specific clinical interventions | Γ | Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ. |

Preregistered aggregation: scope-matched. Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice. Forced broad mitochondrial transcription loss is not normal aging or proof of sporadic initiation; inclusions are not equivalent to Lewy proteinopathy; original body unavailable here.

[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation. This developmental lineage deletion establishes functional parkinsonism, not early neuron death; retained somatic integrity limits marker-based degeneration claims; linked erratum details unexamined.

[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so. Constitutive combined genetic stress models conditional vulnerability, not sporadic deletion primacy; Parkin loss does not increase total mutation burden and levodopa is symptomatic rescue.

[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects. Constitutive fly loss and transgenic rescue do not establish spontaneous human disease or distinguish every Parkin function from bioenergetics.

[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway. The abstract emphasizes muscle and fertility; it cannot be credited as a distinct mammalian neuronal-survival experiment or evidence of sporadic primacy.

[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements. This is an age- and insult-specific negative result, not exclusion of late-life combined Parkin/mutation pathology.

[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss. Germline Parkin deletion compensates; PGC-1alpha survival rescue is in PARIS overexpression rather than a selective human-ageing lesion; human tissue remains associative.

[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration. The same PARIS/Parkin platform is a mechanistic extension rather than an independent sporadic initiation line; organelle markers do not independently prove cell death.

[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression. TH immunostaining alone may conflate identity and survival; constitutive and overexpression methods constrain inference; related PARIS biology shares failure modes.

[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings. Pharmacological specificity and constructed models restrict generalization; multiple models in one programme are not independent human etiological confirmation.

[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons. Absence of loss-of-function pathology does not refute a pathogenic CHCHD2 gain-of-function mutation; gene identity alone cannot diagnose respiratory failure.

[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation. A familial pathogenic mutation with inferred IDE effects is not proof that ordinary bioenergetic decline initiates sporadic PD; direction requires temporal separation.

[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy. A protein-triggered model supports a modifiable downstream quality-control contribution; it does not establish mitochondrial-first onset in humans.

[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment. The demonstrated phenotype is immune-context-dependent axonal dysfunction, not established nigral cell death or unconditional respiratory-loss sufficiency.

[28] PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum. Mutant huntingtin represses PGC-1alpha upstream; global biogenesis loss and overexpression rescue support contribution within genetic HD, not sporadic mitochondrial initiation.

[30] Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice. A pan-PPAR agonist is pleiotropic; benefits under mutant HTT do not identify biogenesis alone or reverse genetic upstream order.

[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model. A-beta acts upstream of pore stress; lifelong knockout and model cognition do not establish sporadic onset or clinical disease modification.

[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls. The rescue starts at four weeks, before disease, rather than reversing established dementia; 3xTg mutations and a roughly twofold transgene are not sporadic etiological proof.

[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations. A severe engineered efflux lesion and indications of death are not normal aging or proof of human universal initiation.

[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation. Protection in a familial transgenic setting supports calcium dependence; the corresponding preprint is the same study, not independent replication or human disease modification.

[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity. A myeloid inflammatory intervention is not selective neuronal mitochondrial restoration, and amyloid-linked effects do not identify the initial sporadic event.

[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan. This is an engaged genetic dissociation between soma preservation and fatal paralysis; it bounds the pore mechanism, not every mitochondrial process or human sporadic ALS.

[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns. Later multi-mutant experiments fail to reproduce disease-trajectory benefit despite engagement; model/background discrepancies remain unresolved.

[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis. Engineered sufficiency does not identify spontaneous sALS initiation; correction details unexamined and reported human-deficiency prevalence is not independently audited here.

[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice. This places protein toxicity before mitochondrial impairment and tests a familial interaction, not a universal mitochondrial initiator.

[58] A prospective randomized trial using prior-study-defined early-ALS eligibility shows less 24-week ALSFRS-R decline with edaravone. This establishes a restricted antioxidant clinical effect, not specific mitochondrial restoration or upstream cause; broad efficacy cannot be inferred from the selected cohort.

[60] EMPOWER finds no dexpramipexole benefit on prespecified combined function/survival or separate efficacy endpoints. A drug-regimen null with uncertain cellular target engagement cannot falsify every mitochondrial driver; an author-name correction is retained.

[61] Olesoxime does not improve 18-month survival or sustained functional endpoints in riluzole-treated ALS. Blood levels do not establish mitochondrial occupancy in target motor neurons; one transient secondary signal is not sustained disease modification.

[62] An adaptive CoQ10 ALS trial finds insufficient promise to proceed, with null secondary outcomes and sensitivity-dependent futility analyses. A futility design is not a conventional superiority trial and does not establish adequate CNS mitochondrial engagement or mechanism absence.

[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure. Negative compound performance constrains translational rationale rather than every mitochondrial mechanism; a marginal single cellular indicator is retained.

[64] High-dose CoQ10 in early PD reaches prespecified futility without clinical UPDRS benefit. This treatment failure does not establish adequate neuronal engagement, timing or complete disproof of bioenergetic contribution.

[65] Long-term NET-PD creatine randomization is stopped for futility on a composite clinical progression outcome. Energy buffering is broad and clinical treatment begins after diagnosis; neuronal mitochondrial correction is not demonstrated by this outcome.

[66] STEADY-PD III isradipine shows no three-year clinical progression benefit or secondary benefit. The original abstract explicitly allows insufficient neuroprotective calcium-channel engagement; a universal engaged-mechanism null would overstate it.

[67] Original UDCA Methods define safety as primary; Results show midbrain MRS energetic changes and a small sensor-gait signal, with null UPDRS group contrasts. Thirty-one were randomized; MRS/gait subsets are smaller, secondary analyses unpowered and unadjusted for multiplicity; no established disease-modifying trajectory or cell-specific adequate engagement.

[68] NADPARK increases brain NAD variably and alters metabolic/inflammatory measures after 30 days. Phase-I biomarker engagement and responder-associated clinical change do not establish progression; response-defined subsets cannot prospectively define scope.

[69] NR-SAFE supports short-term high-dose tolerability and blood NAD elevation in 20 patients. Clinical change covaries with time since levodopa; four weeks and blood metabolites cannot establish mitochondrial disease modification.

[70] 2CARE high-dose CoQ10 in genetic HD is stopped for futility without functional-capacity or survival benefit. The initiating HTT mutation is distinct from mitochondrial support; no adequate neuronal biochemical engagement is established by the null clinical outcome.

Tally: 37 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

### Cap audit, precedence and Β/Γ/Δ boundary

Convergent endogenous neuronal lesions cross model-sufficiency boundaries as a set. That set is not re-capped because some supporting human studies are associative. The separate leap to ordinary sporadic etiological primacy remains Γ. HD loss/rescue crosses contextual contribution while the genetic HTT initiating event remains intact. Human biomarker engagement does not cross a clinical trajectory threshold.

Gamma hard-rule audit: In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular. Droplet ageing is not relied on. Organoid toxicity without organismal follow-through is not used as the causal gate. Exogenous seeding alone limits PFF-to-sporadic initiation inference. Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately.

SC1 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation.

SC4 cap: “Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.” Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy.

SC5 cap: “Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.” Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality.

SC6 cap: “Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.” Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ.

SC1 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation.

SC2 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Tfam disruption, conditional adult Parkin/PARIS loss with Nissl-confirmed degeneration, combined POLG/Parkin stress and rat complex-IV editing provide distinct endogenous routes to disease-relevant injury. Model-level mitochondrial sufficiency reaches Ζ as a set. Ndufs2 primarily produces dysfunction with somatic survival and is not falsely counted as death. Contradictory pore effects and lesion severity block a uniform Η trajectory claim; sporadic human primacy is a separate subclaim.

SC3 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Endogenous PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice and matched gain-of-function/PPAR approaches preserve phenotypes. This is genuine context-dependent biogenesis contribution (Ε), despite pleiotropy. Mutant HTT is upstream; donor-cell glycolytic and isolated-respiration counterexamples limit generalization and exclusive bioenergetic explanation.

SC4 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy.

SC5 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality.

SC6 field-valid definition: “
- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo
- Selective pathway inhibition that changes onset/progression while preserving broader viability
- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ.

### Upward threshold ladder

SC1 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A descriptive association row cannot be raised by relabelling another causal claim; establish a separate intervention subclaim.

SC2 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes. 

SC2 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes. 

SC2 Ζ: “Requires:
- Multiple independent causal lines in vivo
- Replication across at least two relevant systems
- Narrowing of major alternative models” Satisfied: yes. 

SC2 Η: “Requires:
- Strong convergent causal evidence across systems
- Intervention-sensitive change in trajectory
- No major unresolved contradiction about whether the mechanism is upstream versus downstream” Satisfied: no. Demonstrate intervention-sensitive disease trajectory in independently replicated physiological lesions with matched rescue, preserved general viability and reconciled pore/survival discrepancies.

SC3 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes. 

SC3 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes. 

SC3 Ζ: “Requires:
- Multiple independent causal lines in vivo
- Replication across at least two relevant systems
- Narrowing of major alternative models” Satisfied: no. Replicate selective endogenous biogenesis rescue in distinct HTT systems with survival rather than broad PPAR or ATP endpoints.

SC4 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Selectively remove or reinstate defined somatic mtDNA deletions before disease in aged neurons and track cell fate with wild-type-copy compensation controls.

SC5 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A pre-onset, mechanistically engaged intervention or credible human natural instrument must separate mitochondria-first from protein-first and multi-hit models by incident disease and longitudinal function.

SC6 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A confirmatory trial must demonstrate relevant brain/cell engagement and sustained functional or survival benefit attributable to the proposed mitochondrial process.

Upper ladder: Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain.

Independence: SC2 convergence uses different endogenous perturbations and mice/rats rather than simply counting TH-stained cells or multiple papers. PARIS extensions, NCLX descendants and cybrid variants share platforms; uncertain cohort overlap is not claimed resolved. Lesion-to-injury causal convergence does not identify the common spontaneous initiator. Ndufs2 dysfunction and CypD fatal-paralysis nulls are explicit discriminators, not positive death or trajectory lines.

Mitochondrial transcription loss [1]: TFAM disruption excludes protein-overexpression as a required route in this model.

Adult quality-control loss and mediator subtraction [10, 5]: Adult PARIS necessity and combined mtDNA stress test developmental compensation and single-lesion sufficiency differently.

Mitochondrial-genome respiratory editing [55]: Rat complex-IV editing tests a different respiratory lesion and neuronal vulnerability; exact correction details remain unexamined.

### Falsification and pitfalls

Mitochondrial biomarker rescue can fail to alter disease trajectory. Engaged CypD deletion improves ATP/calcium buffering and motor-neuron survival but not denervation, progression or lifespan in three SOD1 models. Additional downgrade: False.

Protein and other metabolic processes can lie upstream. HTT repression, alpha-synuclein import inhibition and SOD1 conductance effects coexist with largely retained HD respiratory reserve. Additional downgrade: False.

Dopamine-marker loss called neuronal death. Original Ndufs2 retrograde-label and compensation Results.

Point-mutation mutator treated as sporadic deletion-specific cause. SC4 differs from combined POLG/Parkin lesions.

Pre-onset transgene protection called late therapeutic reversal. Original NCLX induction at four weeks.

All failed therapies declared adequately engaged. Isradipine limitation and UDCA/NADPARK biomarker specificity.

Inherited HD called sporadic mitochondrial-first disease. Registered wording is scientifically ill-posed and explicitly qualified.

Provider substituted reviews or irrelevant knockout cited as original checks. Consensus missing four focal originals and irrelevant alpha9 compensation example.

Respiration equated to total ATP metabolism. HD glycolysis, PGK1 and Ndufs2 glycolytic compensation.

### Adversarial steelman: above, then below

The best case for Δ or higher for mitochondrial-first causality combines endogenous lesion sufficiency, mtDNA transfer and early NCLX changes before model plaques, plus metabolic human engagement. These establish more than passive association. They do not yet isolate the age-related initiating process across sporadic diseases, and HD begins with HTT. The model sufficiency set receives Ζ separately rather than being suppressed.

A Β-only account misses adult mediator subtraction, Nissl-confirmed progressive loss and respiratory genetic editing. The nominal inference is supported mechanistically even though its ordinary human etiological apex is unresolved.

Γ is appropriate for SC5 while Ζ/Ε preserve narrower causal successes. Neither all-mitochondria-first nor mitochondria-as-passive-consequence fits the full evidence. Null drug regimens constrain implementation; only verified mechanistic nulls constrain the precise driver.

### Final score, causal direction and M/S/D

Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast.

In the broad disease class, mitochondrial processes can amplify injury and set reserve; removal/rescue changes selected model trajectories. Severe mitochondrial lesions can initiate disease in their own scope, and metabolic reserve can be permissive. Neither observation establishes a common rate-limiting human initiator; the class-level role does not erase narrow sufficiency.

Momentum: Mechanistic only. 2025 complex-IV editing and 2026 neuronal MCU loss/mitochondrial transfer test causal or rescue boundaries. The examined UDCA and NR phase-I/II reports do not establish current recruitment or a pending decisive clinical result.

Stability: Stable. No verified named pending human result is asserted likely to change the nominal primacy score imminently. A pre-onset subtype-specific engaged clinical benefit would change SC5/SC6.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

In baseline genotype-, reserve- and protein-state-defined aged cohorts or validated natural-instrument cohorts, selectively preserve the implicated mitochondrial process before protein pathology, with matched protein-directed perturbation and mechanistic rescue. Follow incident disease, cell fate and function. Predefine disease-specific boundaries rather than pooling genetic HD with sporadic syndromes.

Readout: Incident adjudicated disease, chronological protein/mitochondrial change, labelled neuronal and axonal survival, motor/cognitive function and lifespan. Controls: Cell-specific engagement, general viability, genotype, baseline reserve, protein burden, developmental compensation, treatment timing and symptomatic medication; selective lesion reinstatement. Supporting: Mitochondrial preservation prevents protein pathology and disease in the predicted baseline strata, with matched rescue and independent natural or clinical confirmation. Falsifying: Adequate early mitochondrial correction leaves onset unchanged, protein-directed perturbation prevents the mitochondrial lesion, or reserve thresholds fail to predict vulnerability.

## RESEARCH TIMELINE

| Year | Milestone | Primary source | Interpretation |
|---|---|---|---|
| 1995 | HD common-deletion negative tissue result | [PMID7599213](https://pubmed.ncbi.nlm.nih.gov/7599213/) | Bulk-cell composition limits interpretation. |
| 1997 | AD platelet cybrid respiratory phenotype | [PMID9339668](https://pubmed.ncbi.nlm.nih.gov/9339668/) | Constructed-cell transfer. |
| 1999 | AD cybrid respiratory-integrity counterexample | [PMID10051601](https://pubmed.ncbi.nlm.nih.gov/10051601/) | Nuclear-background and selection boundaries. |
| 2006 | Single-neuron PD mtDNA deletions | [PMID16604072](https://pubmed.ncbi.nlm.nih.gov/16604072/) | Functional association. |
| 2006 | HTT-PGC-1alpha loss/rescue | [PMID17018277](https://pubmed.ncbi.nlm.nih.gov/17018277/) | Genetically initiated contextual contribution. |
| 2007 | MitoPark neuronal TFAM lesion | [PMID17227870](https://pubmed.ncbi.nlm.nih.gov/17227870/) | Engineered mitochondrial sufficiency. |
| 2008 | CypD-dependent AD stress/cognition | [PMID18806802](https://pubmed.ncbi.nlm.nih.gov/18806802/) | Amyloid-model contribution. |
| 2009 | ALS CypD lifespan result | [PMID19272377](https://pubmed.ncbi.nlm.nih.gov/19272377/) | Sex/model-specific positive. |
| 2011 | Adult Parkin/PARIS subtraction | [PMID21376232](https://pubmed.ncbi.nlm.nih.gov/21376232/) | Nissl-confirmed progressive loss. |
| 2013 | ALS engaged pore rescue without lifespan gain | [PMID23486940](https://pubmed.ncbi.nlm.nih.gov/23486940/) | Compartment versus organismal trajectory. |
| 2013 | EMPOWER null clinical result | [PMID24067398](https://pubmed.ncbi.nlm.nih.gov/24067398/) | Drug-regimen failure. |
| 2014 | CoQ10 PD futility | [PMID24664227](https://pubmed.ncbi.nlm.nih.gov/24664227/) | No confirmed adequate-neuron engagement. |
| 2015 | Parkin/POLG interaction | [PMID26182419](https://pubmed.ncbi.nlm.nih.gov/26182419/) | Age-dependent double-hit loss. |
| 2015 | Creatine PD futility | [PMID25668262](https://pubmed.ncbi.nlm.nih.gov/25668262/) | Clinical energy-buffering regimen. |
| 2016 | Healthy-age mtDNA compensation | [PMID27874000](https://pubmed.ncbi.nlm.nih.gov/27874000/) | Published online 2016; ageing reserve. |
| 2017 | HD 2CARE futility | [PMID27913695](https://pubmed.ncbi.nlm.nih.gov/27913695/) | Functional/survival outcome. |
| 2017 | Restricted edaravone ALS benefit | [PMID28522181](https://pubmed.ncbi.nlm.nih.gov/28522181/) | Antioxidant effect; mediator unresolved. |
| 2019 | NCLX AD loss and early rescue | [PMID31467276](https://pubmed.ncbi.nlm.nih.gov/31467276/) | Prevention in familial-transgene mice. |
| 2020 | HD glycolytic deficit and metabolite rescue | [PMID30768179](https://pubmed.ncbi.nlm.nih.gov/30768179/) | Online 2019; journal 2020; respiration mostly retained. |
| 2021 | Ndufs2 functional parkinsonism with compensation | [PMID34732887](https://pubmed.ncbi.nlm.nih.gov/34732887/) | Marker loss distinguished from death. |
| 2022 | NADPARK brain NAD engagement | [PMID35235774](https://pubmed.ncbi.nlm.nih.gov/35235774/) | Phase-I metabolic signal. |
| 2023 | UDCA safety/energetic trial | [PMID37246815](https://pubmed.ncbi.nlm.nih.gov/37246815/) | Unpowered secondary clinical analyses. |
| 2024 | Idiopathic PD complex-I subtypes | [PMID38684731](https://pubmed.ncbi.nlm.nih.gov/38684731/) | Postmortem heterogeneity. |
| 2025 | Rat complex-IV genetic sufficiency | [PMID40069360](https://pubmed.ncbi.nlm.nih.gov/40069360/) | Engineered ALS-like injury. |
| 2026 | Neuronal MCU loss in AD mice | [PMID42174122](https://pubmed.ncbi.nlm.nih.gov/42174122/) | Same study as indexed preprint. |
| 2026 | Encapsulated mitochondrial transfer | [PMID41856111](https://pubmed.ncbi.nlm.nih.gov/41856111/) | Model rescue; correction details unexamined. |

## KNOWLEDGE GAPS

Separate actual neuron/axon survival from neurotransmitter phenotype and somatic compensation.

Identify deletion-specific causal effects and wild-type-copy compensation before sporadic PD onset.

Resolve cell type and bioenergetic subtype prospectively rather than selecting deficient brains after death.

Compare glycolytic reserve, respiration and ATP-demand failure instead of equating them.

Reconcile CypD lifespan discrepancies across sex, background and SOD1 alleles using blinded matched designs.

Test NCLX/MCU and quality-control rescue after established pathology rather than only early prevention.

Pair human bioenergetic engagement with selective sustained clinical benefit and medication-aware endpoints.

Define mitochondrial mediators separately in inherited HTT disease and sporadic AD/PD/ALS.

## METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

## REVIEWER NOTES

70 primary reports examined, six with selected original-body sections; 64 abstract/status-only. No complete-paper/supplement audit. Γ overall is scope-matched SC5, while model sufficiency is Ζ and HD contribution Ε. Inherited HD wording and clinical engagement limits are explicit. Two Consensus Pro queries, zero API/Deep; one SciSpace discovery query, one deduplicated matched primary lead. Carried controls are not fresh blinded calibration.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14.

**Scope of checks.** All 70 reference PMIDs verified against PubMed records (70/70 resolve to the stated title, first author, journal and year; no retractions or expressions of concern). Ten load-bearing claims spot-checked against source abstracts or original bodies (PMID 23486940, 32227247, 27913695, 25668262, 28522181, 34732887, 26182419, 37246815, 35235774, 30768179), plus the UDCA randomisation and subset counts against the original Results. Scoring logic re-derived against `hsef-hypothesis-review-v5/SKILL.md` Step 3 and `references/hsef-framework.md` (caps, scope-matched aggregation, confidence band, momentum artifact, role derivation). No level or confidence change.

| ID | Severity | Location | Original → corrected | Evidence |
|---|---|---|---|---|
| M-1 | Major | Consensus provenance reconciliation (9 October 2026) | "The earlier adversarial approval refers to its original edition" → "No earlier adversarial approval exists for this case" | No adversarial approval section, banner or approval line exists in any edition of this case, including the pre-revision copy in `hsef_v53_popularity_ranks_26_30_2026-10-07`. The sentence asserted an approval that was never issued. Introduced by the 9 October revision — a regression relative to the earlier edition. |
| M-2 | Minor | REFERENCES [31] | ", et al." (author dropped) → "HD iPSC Consortium." | PubMed CollectiveName for PMID 30768179 is "HD iPSC Consortium". Reference-builder collective-author defect. |
| M-3 | Minor | REFERENCES [58] | ", , et al." → "Writing Group, Edaravone (MCI-186) ALS 19 Study Group." | PubMed CollectiveName fields for PMID 28522181 (two collective authors, no individual authors). |
| M-4 | Minor | REFERENCES [64] | ", Beal MF, Oakes D et al." → "Parkinson Study Group QE3 Investigators, Beal MF, Oakes D et al." | PubMed CollectiveName for PMID 24664227. |
| M-5 | Minor | REFERENCES [65] | ", Kieburtz K, Tilley BC et al." → "Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC et al." | PubMed CollectiveName for PMID 25668262. |
| M-6 | Minor | REFERENCES [66] | ", et al." → "Parkinson Study Group STEADY-PD III Investigators." | PubMed CollectiveName for PMID 32227247 (sole author). |
| M-7 | Minor | `final_score.confidence_rationale` (scorecard, 3 occurrences) | "density, heterogeneous controls and incomplete access set the confidence" → rationale restated in terms of evidence density and reproducibility, with access depth explicitly excluded | Framework: "Confidence reflects evidence density and reproducibility." Lead policy on confidence bands (2026-10-14): access depth is never a valid determinant. Re-derived band after striking it: the review documents substantive reproducibility concerns (complex-I subtype heterogeneity, cybrid nuclear-background and preparation differences, unreconciled CypD survival discrepancies), so **Moderate stands**. |
| M-8 | Editorial | REFERENCES [44]; evidence card [60] | "DOI: ." (empty field) removed; "ErratumIn: PMIDnot supplied." → "ErratumIn: PMID not supplied." | PubMed holds no DOI for PMID 10939564 (the journal DOI is a legacy Wiley identifier not indexed by NLM), so the field is dropped rather than left empty. The ErratumIn entry for PMID 24067398 carries a RefSource but no PMID; the glued string was a renderer defect. |

**Rejected findings (checked, no change).**
1. **Headline level Γ and scope-matched derivation.** Re-derived: the central claim is broadly scoped (etiological apex across sporadic AD, PD, HD, ALS); SC5 is the only scope-matched subclaim and is Γ. SC2 Ζ is explicitly scope-restricted to prespecified genetic lesions and toxins and therefore cannot set the headline. Alternatives are reported as required (weakest-link Β, primary-subclaim Γ). No change.
2. **"Best-supported rival" renderer artifact.** Checked `models_evaluated[0]` / rank order: rank 1 is "Multi-hit convergent loop", which is not this review's nominal model (the nominal "Mitochondrial-first cascade" ranks 4). The prose is correct as written.
3. **Momentum "Mechanistic only".** Correct value and a naming artifact is present (2025 rat complex-IV editing, 2026 neuronal MCU loss and encapsulated-mitochondrial transfer). Per lead policy, completed publications could not have supported "Decisive work underway" in any case; the review does not claim it.
4. **REVIEWER NOTES versus the spliced Consensus section.** The notes state two Consensus Pro queries and zero API/Deep calls, which is consistent with the provenance section and with the METHODS statement; there is no "no Consensus work was performed" claim to reconcile. No change.
5. **Citation years.** Reference [16] prints 2023 against a PubMed e-pub year of 2022; within the ±1 print/e-pub convention. Rejected.
6. **PubMed title glueing.** PubMed renders the title of PMID 31316206 as "Pink1mice"; the review's "Pink1-/- mice" is the correct form. Rejected per convention.
7. **UDCA participant count.** The abstract says 30 participants; the review says 31 randomised with 25 contributing 31P-MRS and a smaller pandemic-limited gait subset. Verified against the original Results (PMC10527073): 31 randomised (20 UDCA, 11 placebo), 25 with paired 31P-MRS, 18 in the gait subset. The review is right and the abstract imprecise. No change.

**Residual limitations.** Six of 70 sources had partial-body examination; the remainder rest on abstract and linked-status metadata, so claims about figure-level detail in the other 64 could not be independently confirmed. The erratum content for PMID 34732887, 40069360 and 41856111 remains unexamined, as the review states. This pass is a source, claim and scoring-logic audit, not a blinded recalibration.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Ekstrand MI, Terzioglu M, Galter D et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America. 2007. [PMID 17227870](https://pubmed.ncbi.nlm.nih.gov/17227870/). DOI: 10.1073/pnas.0605208103. Access: abstract_metadata. Study: PMID17227870.

2. González-Rodríguez P, Zampese E, Stout KA et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021. [PMID 34732887](https://pubmed.ncbi.nlm.nih.gov/34732887/). DOI: 10.1038/s41586-021-04059-0. Access: full_text_partial. Study: PMID34732887.

3. Kraytsberg Y, Kudryavtseva E, McKee AC et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature genetics. 2006. [PMID 16604072](https://pubmed.ncbi.nlm.nih.gov/16604072/). DOI: 10.1038/ng1778. Access: abstract_metadata. Study: PMID16604072.

4. Bender A, Krishnan KJ, Morris CM et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature genetics. 2006. [PMID 16604074](https://pubmed.ncbi.nlm.nih.gov/16604074/). DOI: 10.1038/ng1769. Access: abstract_metadata. Study: PMID16604074.

5. Pickrell AM, Huang CH, Kennedy SR et al. Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron. 2015. [PMID 26182419](https://pubmed.ncbi.nlm.nih.gov/26182419/). DOI: 10.1016/j.neuron.2015.06.034. Access: full_text_partial. Study: PMID26182419.

6. Park J, Lee SB, Lee S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006. [PMID 16672980](https://pubmed.ncbi.nlm.nih.gov/16672980/). DOI: 10.1038/nature04788. Access: abstract_metadata. Study: PMID16672980.

7. Clark IE, Dodson MW, Jiang C et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006. [PMID 16672981](https://pubmed.ncbi.nlm.nih.gov/16672981/). DOI: 10.1038/nature04779. Access: abstract_metadata. Study: PMID16672981.

8. Dölle C, Flønes I, Nido GS et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature communications. 2016. [PMID 27874000](https://pubmed.ncbi.nlm.nih.gov/27874000/). DOI: 10.1038/ncomms13548. Access: abstract_metadata. Study: PMID27874000.

9. Dai Y, Clark J, Zheng K et al. Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicology and teratology. 2014. [PMID 25450660](https://pubmed.ncbi.nlm.nih.gov/25450660/). DOI: 10.1016/j.ntt.2014.10.004. Access: abstract_metadata. Study: PMID25450660.

10. Shin JH, Ko HS, Kang H et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell. 2011. [PMID 21376232](https://pubmed.ncbi.nlm.nih.gov/21376232/). DOI: 10.1016/j.cell.2011.02.010. Access: full_text_partial. Study: Parkin-PARIS-platform.

11. Stevens DA, Lee Y, Kang HC et al. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America. 2015. [PMID 26324925](https://pubmed.ncbi.nlm.nih.gov/26324925/). DOI: 10.1073/pnas.1500624112. Access: abstract_metadata. Study: Parkin-PARIS-platform.

12. Kumar M, Acevedo-Cintrón J, Jhaldiyal A et al. Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem cell reports. 2020. [PMID 32795422](https://pubmed.ncbi.nlm.nih.gov/32795422/). DOI: 10.1016/j.stemcr.2020.07.013. Access: abstract_metadata. Study: Parkin-PARIS-platform.

13. Pirooznia SK, Yuan C, Khan MR et al. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular neurodegeneration. 2020. [PMID 32138754](https://pubmed.ncbi.nlm.nih.gov/32138754/). DOI: 10.1186/s13024-020-00363-x. Access: abstract_metadata. Study: Parkin-PARIS-platform.

14. Jo A, Lee Y, Kam TI et al. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Science translational medicine. 2021. [PMID 34321320](https://pubmed.ncbi.nlm.nih.gov/34321320/). DOI: 10.1126/scitranslmed.aax8891. Access: abstract_metadata. Study: Parkin-PARIS-platform.

15. Nguyen MK, McAvoy K, Liao SC et al. Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2. Human molecular genetics. 2022. [PMID 34791217](https://pubmed.ncbi.nlm.nih.gov/34791217/). DOI: 10.1093/hmg/ddab329. Access: abstract_metadata. Study: PMID34791217.

16. Fan L, Zhang S, Li X et al. CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease. Brain pathology (Zurich, Switzerland). 2023. [PMID 36322611](https://pubmed.ncbi.nlm.nih.gov/36322611/). DOI: 10.1111/bpa.13124. Access: abstract_metadata. Study: PMID36322611.

17. Di Maio R, Barrett PJ, Hoffman EK et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science translational medicine. 2016. [PMID 27280685](https://pubmed.ncbi.nlm.nih.gov/27280685/). DOI: 10.1126/scitranslmed.aaf3634. Access: abstract_metadata. Study: PMID27280685.

18. Geibl FF, Henrich MT, Xie Z et al. α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease. Molecular neurodegeneration. 2024. [PMID 39379975](https://pubmed.ncbi.nlm.nih.gov/39379975/). DOI: 10.1186/s13024-024-00756-2. Access: abstract_metadata. Study: PMID39379975.

19. Flønes IH, Toker L, Sandnes DA et al. Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease. Nature communications. 2024. [PMID 38684731](https://pubmed.ncbi.nlm.nih.gov/38684731/). DOI: 10.1038/s41467-024-47867-4. Access: abstract_metadata. Study: PMID38684731.

20. Kokotos AC, Antoniazzi AM, Unda SR et al. Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits. Science advances. 2024. [PMID 39167658](https://pubmed.ncbi.nlm.nih.gov/39167658/). DOI: 10.1126/sciadv.adn6016. Access: abstract_metadata. Study: PMID39167658.

21. Fang TZ, Sun Y, Pearce AC et al. Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model. Nature communications. 2023. [PMID 37957154](https://pubmed.ncbi.nlm.nih.gov/37957154/). DOI: 10.1038/s41467-023-42876-1. Access: abstract_metadata. Study: PMID37957154.

22. Du S, Long Q, Zhou Y et al. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models. Cell. 2026. [PMID 41856111](https://pubmed.ncbi.nlm.nih.gov/41856111/). DOI: 10.1016/j.cell.2026.02.023. Access: abstract_metadata. Study: PMID41856111.

23. Matheoud D, Cannon T, Voisin A et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice. Nature. 2019. [PMID 31316206](https://pubmed.ncbi.nlm.nih.gov/31316206/). DOI: 10.1038/s41586-019-1405-y. Access: abstract_metadata. Study: PMID31316206.

24. Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat, and Parkinson's disease. Environmental health perspectives. 2011. [PMID 21269927](https://pubmed.ncbi.nlm.nih.gov/21269927/). DOI: 10.1289/ehp.1002839. Access: abstract_metadata. Study: PMID21269927.

25. Jishi A, Hu D, Shang Y et al. BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease. Acta neuropathologica communications. 2024. [PMID 39709505](https://pubmed.ncbi.nlm.nih.gov/39709505/). DOI: 10.1186/s40478-024-01915-8. Access: abstract_metadata. Study: PMID39709505.

26. Siuda J, Jasinska-Myga B, Boczarska-Jedynak M et al. Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism & related disorders. 2014. [PMID 25226871](https://pubmed.ncbi.nlm.nih.gov/25226871/). DOI: 10.1016/j.parkreldis.2014.08.019. Access: abstract_metadata. Study: PMID25226871.

27. Wei W, Keogh MJ, Wilson I et al. Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta neuropathologica communications. 2017. [PMID 28153046](https://pubmed.ncbi.nlm.nih.gov/28153046/). DOI: 10.1186/s40478-016-0404-6. Access: abstract_metadata. Study: PMID28153046.

28. Cui L, Jeong H, Borovecki F et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006. [PMID 17018277](https://pubmed.ncbi.nlm.nih.gov/17018277/). DOI: 10.1016/j.cell.2006.09.015. Access: abstract_metadata. Study: PMID17018277.

29. Weydt P, Pineda VV, Torrence AE et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell metabolism. 2006. [PMID 17055784](https://pubmed.ncbi.nlm.nih.gov/17055784/). DOI: 10.1016/j.cmet.2006.10.004. Access: abstract_metadata. Study: PMID17055784.

30. Chandra A, Sharma A, Calingasan NY et al. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Human molecular genetics. 2016. [PMID 27008868](https://pubmed.ncbi.nlm.nih.gov/27008868/). DOI: 10.1093/hmg/ddw095. Access: abstract_metadata. Study: PMID27008868.

31. HD iPSC Consortium. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. Human molecular genetics. 2020. [PMID 30768179](https://pubmed.ncbi.nlm.nih.gov/30768179/). DOI: 10.1093/hmg/ddy430. Access: full_text_partial. Study: HD-iPSC-Consortium.

32. Chen X, Bonilla E, Sciacco M et al. Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients. Biochimica et biophysica acta. 1995. [PMID 7599213](https://pubmed.ncbi.nlm.nih.gov/7599213/). DOI: 10.1016/0925-4439(95)00032-y. Access: abstract_metadata. Study: PMID7599213.

33. Swerdlow RH, Parks JK, Cassarino DS et al. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochemical and biophysical research communications. 1999. [PMID 10441489](https://pubmed.ncbi.nlm.nih.gov/10441489/). DOI: 10.1006/bbrc.1999.1095. Access: abstract_metadata. Study: PMID10441489.

34. Hamilton J, Pellman JJ, Brustovetsky T et al. Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease. Human molecular genetics. 2016. [PMID 27131346](https://pubmed.ncbi.nlm.nih.gov/27131346/). DOI: 10.1093/hmg/ddw133. Access: abstract_metadata. Study: PMID27131346.

35. Oláh J, Klivényi P, Gardián G et al. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. The FEBS journal. 2008. [PMID 18721135](https://pubmed.ncbi.nlm.nih.gov/18721135/). DOI: 10.1111/j.1742-4658.2008.06612.x. Access: abstract_metadata. Study: PMID18721135.

36. Hamilton J, Brustovetsky T, Khanna R et al. Mutant huntingtin does not cross the mitochondrial outer membrane. Human molecular genetics. 2020. [PMID 32821928](https://pubmed.ncbi.nlm.nih.gov/32821928/). DOI: 10.1093/hmg/ddaa185. Access: abstract_metadata. Study: PMID32821928.

37. Soyal SM, Felder TK, Auer S et al. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Human molecular genetics. 2012. [PMID 22589246](https://pubmed.ncbi.nlm.nih.gov/22589246/). DOI: 10.1093/hmg/dds177. Access: abstract_metadata. Study: PMID22589246.

38. Du H, Guo L, Fang F et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nature medicine. 2008. [PMID 18806802](https://pubmed.ncbi.nlm.nih.gov/18806802/). DOI: 10.1038/nm.1868. Access: abstract_metadata. Study: PMID18806802.

39. Samanta S, Akhter F, Roy A et al. New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease. Brain : a journal of neurology. 2024. [PMID 38146639](https://pubmed.ncbi.nlm.nih.gov/38146639/). DOI: 10.1093/brain/awad432. Access: abstract_metadata. Study: PMID38146639.

40. Jadiya P, Kolmetzky DW, Tomar D et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. Nature communications. 2019. [PMID 31467276](https://pubmed.ncbi.nlm.nih.gov/31467276/). DOI: 10.1038/s41467-019-11813-6. Access: full_text_partial. Study: NCLX-calcium-platform.

41. Jadiya P, Cohen HM, Kolmetzky DW et al. Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline. iScience. 2023. [PMID 36936788](https://pubmed.ncbi.nlm.nih.gov/36936788/). DOI: 10.1016/j.isci.2023.106296. Access: abstract_metadata. Study: NCLX-calcium-platform.

42. Jadiya P, Berezhnaya E, Kolmetzky DW et al. Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression. The EMBO journal. 2026. [PMID 42174122](https://pubmed.ncbi.nlm.nih.gov/42174122/). DOI: 10.1038/s44318-026-00809-w. Access: abstract_metadata. Study: NCLX-calcium-platform.

43. Swerdlow RH, Parks JK, Cassarino DS et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997. [PMID 9339668](https://pubmed.ncbi.nlm.nih.gov/9339668/). DOI: 10.1212/wnl.49.4.918. Access: abstract_metadata. Study: AD-cybrid-platform.

44. Khan SM, Cassarino DS, Abramova NN et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Annals of neurology. 2000. [PMID 10939564](https://pubmed.ncbi.nlm.nih.gov/10939564/). Access: abstract_metadata. Study: AD-cybrid-platform.

45. Silva DF, Santana I, Esteves AR et al. Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease. Current Alzheimer research. 2013. [PMID 22746213](https://pubmed.ncbi.nlm.nih.gov/22746213/). DOI: 10.2174/1567205011310020008. Access: abstract_metadata. Study: AD-cybrid-platform.

46. Ito S, Ohta S, Nishimaki K et al. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 1999. [PMID 10051601](https://pubmed.ncbi.nlm.nih.gov/10051601/). DOI: 10.1073/pnas.96.5.2099. Access: abstract_metadata. Study: PMID10051601.

47. Weidling IW, Wilkins HM, Koppel SJ et al. Mitochondrial DNA Manipulations Affect Tau Oligomerization. Journal of Alzheimer's disease : JAD. 2020. [PMID 32804126](https://pubmed.ncbi.nlm.nih.gov/32804126/). DOI: 10.3233/JAD-200286. Access: abstract_metadata. Study: AD-cybrid-platform.

48. Kemna RE, Kueck PJ, Honea R et al. Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. [PMID 40596736](https://pubmed.ncbi.nlm.nih.gov/40596736/). DOI: 10.1002/alz.70390. Access: abstract_metadata. Study: AD-cybrid-platform.

49. Han J, Park H, Maharana C et al. Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function. Theranostics. 2021. [PMID 34522215](https://pubmed.ncbi.nlm.nih.gov/34522215/). DOI: 10.7150/thno.59776. Access: abstract_metadata. Study: PMID34522215.

50. Lee H, Cho S, Kim MJ et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell reports. 2023. [PMID 37777962](https://pubmed.ncbi.nlm.nih.gov/37777962/). DOI: 10.1016/j.celrep.2023.113183. Access: abstract_metadata. Study: PMID37777962.

51. Wilson EN, Wang C, Swarovski MS et al. TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models. Nature neuroscience. 2024. [PMID 38539014](https://pubmed.ncbi.nlm.nih.gov/38539014/). DOI: 10.1038/s41593-024-01610-w. Access: abstract_metadata. Study: PMID38539014.

52. Parone PA, Da Cruz S, Han JS et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013. [PMID 23486940](https://pubmed.ncbi.nlm.nih.gov/23486940/). DOI: 10.1523/JNEUROSCI.1119-12.2013. Access: abstract_metadata. Study: PMID23486940.

53. Martin LJ, Gertz B, Pan Y et al. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Experimental neurology. 2009. [PMID 19272377](https://pubmed.ncbi.nlm.nih.gov/19272377/). DOI: 10.1016/j.expneurol.2009.02.015. Access: abstract_metadata. Study: PMID19272377.

54. Yu CH, Davidson S, Harapas CR et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020. [PMID 33031745](https://pubmed.ncbi.nlm.nih.gov/33031745/). DOI: 10.1016/j.cell.2020.09.020. Access: abstract_metadata. Study: PMID33031745.

55. Cheng M, Lu D, Li K et al. Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis. Nature neuroscience. 2025. [PMID 40069360](https://pubmed.ncbi.nlm.nih.gov/40069360/). DOI: 10.1038/s41593-025-01896-4. Access: abstract_metadata. Study: PMID40069360.

56. Israelson A, Arbel N, Da Cruz S et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010. [PMID 20797535](https://pubmed.ncbi.nlm.nih.gov/20797535/). DOI: 10.1016/j.neuron.2010.07.019. Access: abstract_metadata. Study: PMID20797535.

57. Zhang F, Wang W, Siedlak SL et al. Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in aging neuroscience. 2015. [PMID 26074815](https://pubmed.ncbi.nlm.nih.gov/26074815/). DOI: 10.3389/fnagi.2015.00100. Access: abstract_metadata. Study: PMID26074815.

58. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2017. [PMID 28522181](https://pubmed.ncbi.nlm.nih.gov/28522181/). DOI: 10.1016/S1474-4422(17)30115-1. Access: abstract_metadata. Study: PMID28522181.

59. Witzel S, Maier A, Steinbach R et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA neurology. 2022. [PMID 35006266](https://pubmed.ncbi.nlm.nih.gov/35006266/). DOI: 10.1001/jamaneurol.2021.4893. Access: abstract_metadata. Study: German-edaravone-cohort.

60. Cudkowicz ME, van den Berg LH, Shefner JM et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet. Neurology. 2013. [PMID 24067398](https://pubmed.ncbi.nlm.nih.gov/24067398/). DOI: 10.1016/S1474-4422(13)70221-7. Access: abstract_metadata. Study: PMID24067398.

61. Lenglet T, Lacomblez L, Abitbol JL et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. European journal of neurology. 2014. [PMID 24447620](https://pubmed.ncbi.nlm.nih.gov/24447620/). DOI: 10.1111/ene.12344. Access: abstract_metadata. Study: PMID24447620.

62. Kaufmann P, Thompson JL, Levy G et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of neurology. 2009. [PMID 19743457](https://pubmed.ncbi.nlm.nih.gov/19743457/). DOI: 10.1002/ana.21743. Access: abstract_metadata. Study: PMID19743457.

63. Vieira FG, LaDow E, Moreno A et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PloS one. 2014. [PMID 25526593](https://pubmed.ncbi.nlm.nih.gov/25526593/). DOI: 10.1371/journal.pone.0091608. Access: abstract_metadata. Study: PMID25526593.

64. Parkinson Study Group QE3 Investigators, Beal MF, Oakes D et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA neurology. 2014. [PMID 24664227](https://pubmed.ncbi.nlm.nih.gov/24664227/). DOI: 10.1001/jamaneurol.2014.131. Access: abstract_metadata. Study: PMID24664227.

65. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015. [PMID 25668262](https://pubmed.ncbi.nlm.nih.gov/25668262/). DOI: 10.1001/jama.2015.120. Access: abstract_metadata. Study: PMID25668262.

66. Parkinson Study Group STEADY-PD III Investigators. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Annals of internal medicine. 2020. [PMID 32227247](https://pubmed.ncbi.nlm.nih.gov/32227247/). DOI: 10.7326/M19-2534. Access: abstract_metadata. Study: PMID32227247.

67. Payne T, Appleby M, Buckley E et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2023. [PMID 37246815](https://pubmed.ncbi.nlm.nih.gov/37246815/). DOI: 10.1002/mds.29450. Access: full_text_partial. Study: PMID37246815.

68. Brakedal B, Dölle C, Riemer F et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell metabolism. 2022. [PMID 35235774](https://pubmed.ncbi.nlm.nih.gov/35235774/). DOI: 10.1016/j.cmet.2022.02.001. Access: abstract_metadata. Study: PMID35235774.

69. Berven H, Kverneng S, Sheard E et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature communications. 2023. [PMID 38016950](https://pubmed.ncbi.nlm.nih.gov/38016950/). DOI: 10.1038/s41467-023-43514-6. Access: abstract_metadata. Study: PMID38016950.

70. McGarry A, McDermott M, Kieburtz K et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017. [PMID 27913695](https://pubmed.ncbi.nlm.nih.gov/27913695/). DOI: 10.1212/WNL.0000000000003478. Access: abstract_metadata. Study: PMID27913695.

## Source-specific evidence cards

### [1] Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

**Shows:** DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.

**Does not show:** Forced broad mitochondrial transcription loss is not normal aging or proof of sporadic initiation; inclusions are not equivalent to Lewy proteinopathy; original body unavailable here.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [2] Disruption of mitochondrial complex I induces progressive parkinsonism.

**Shows:** Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.

**Does not show:** This developmental lineage deletion establishes functional parkinsonism, not early neuron death; retained somatic integrity limits marker-based degeneration claims; linked erratum details unexamined.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Loss of MCI induces metabolic reprogramming:paragraph0, 0:Loss of MCI induces metabolic reprogramming:paragraph1, 0:Loss of MCI induces metabolic reprogramming:paragraph2, 1:Early axonal dysfunction after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph1, 4:Nigral determinants of motor disability:paragraph2, 4:Nigral determinants of motor disability:paragraph3, 4:Nigral determinants of motor disability:paragraph4. No complete-paper or supplement audit claimed. ErratumIn: PMID35149834. Subclaims: SC2, SC5.

### [3] Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons.

**Shows:** Single aged substantia-nigra neurons contain clonally expanded mtDNA deletions associated with respiratory deficiency.

**Does not show:** Postmortem functional association lacks deletion-selective manipulation, pre-onset order or tracked neuronal fate.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [4] High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease.

**Shows:** High mtDNA deletion burdens accompany respiratory-chain deficiency in aged and PD substantia nigra.

**Does not show:** Aged controls also carry high burdens; lesion presence does not establish differential death or etiological primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [5] Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress.

**Shows:** Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.

**Does not show:** Constitutive combined genetic stress models conditional vulnerability, not sporadic deletion primacy; Parkin loss does not increase total mutation burden and levodopa is symptomatic rescue.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph5, 1:RESULTS:paragraph10, 1:RESULTS:paragraph11, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4, SC5.

### [6] Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin.

**Shows:** Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.

**Does not show:** Constitutive fly loss and transgenic rescue do not establish spontaneous human disease or distinguish every Parkin function from bioenergetics.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [7] Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.

**Shows:** Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.

**Does not show:** The abstract emphasizes muscle and fertility; it cannot be credited as a distinct mammalian neuronal-survival experiment or evidence of sporadic primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [8] Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease.

**Shows:** Aged controls compensate deletion burden with increased mtDNA copy number; this maintenance of wild-type mtDNA is deficient in PD neurons.

**Does not show:** Cross-sectional surviving cells do not resolve whether failed compensation precedes disease or follows proteinopathy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [9] Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice.

**Shows:** Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.

**Does not show:** This is an age- and insult-specific negative result, not exclusion of late-life combined Parkin/mutation pathology.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [10] PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.

**Shows:** Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.

**Does not show:** Germline Parkin deletion compensates; PGC-1alpha survival rescue is in PARIS overexpression rather than a selective human-ageing lesion; human tissue remains associative.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph18, 1:RESULTS:paragraph19, 1:RESULTS:paragraph20, 1:RESULTS:paragraph22. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [11] Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.

**Shows:** Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.

**Does not show:** The same PARIS/Parkin platform is a mechanistic extension rather than an independent sporadic initiation line; organelle markers do not independently prove cell death.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [12] Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons.

**Shows:** PARIS CRISPR knockdown restores biogenesis and mitochondrial function in PARKIN-deficient human dopamine neurons while mitophagy defects persist.

**Does not show:** In-vitro genetic cells separate biogenesis from mitophagy but do not demonstrate organismal progression or sporadic upstream order.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [13] PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.

**Shows:** Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.

**Does not show:** TH immunostaining alone may conflate identity and survival; constitutive and overexpression methods constrain inference; related PARIS biology shares failure modes.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [14] PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.

**Shows:** Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.

**Does not show:** Pharmacological specificity and constructed models restrict generalization; multiple models in one programme are not independent human etiological confirmation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [15] Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2.

**Shows:** DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.

**Does not show:** Absence of loss-of-function pathology does not refute a pathogenic CHCHD2 gain-of-function mutation; gene identity alone cannot diagnose respiratory failure.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [16] CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease.

**Shows:** Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.

**Does not show:** A familial pathogenic mutation with inferred IDE effects is not proof that ordinary bioenergetic decline initiates sporadic PD; direction requires temporal separation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [17] α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.

**Shows:** Modified alpha-synuclein inhibits TOM20-mediated import; endogenous alpha-synuclein lowering preserves import in a PD model and human tissue shows the interaction.

**Does not show:** Protein-driven mitochondrial disruption provides a reverse-direction route; import or in-vitro TOM20 rescue alone is not human survival or initiation proof.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [18] α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease.

**Shows:** Injected alpha-synuclein PFFs produce neuronal loss and mitochondrial ATP/redox abnormalities in vulnerable dopamine and cholinergic populations.

**Does not show:** Forced seeding places protein pathology upstream experimentally; it cannot establish natural onset or turn a mitochondrial proximal mediator into the initiating cause.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID38168401. Subclaims: SC2, SC5.

### [19] Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease.

**Shows:** Idiopathic PD stratifies by widespread neuronal complex-I deficiency, with distinct molecular and clinical profiles and deletion burden.

**Does not show:** Postmortem subtype classification is not pre-onset causal identification; many cases lack extra-nigral impairment and outcome-defined strata cannot rescue a universal claim.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4, SC5.

### [20] Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits.

**Shows:** Modest PGK1 augmentation improves neuronal ATP kinetics and synaptic function; viral expression protects dopamine axons from metabolic lesions.

**Does not show:** Glycolytic support and axonal function are broader than mitochondrial respiration; induced lesions and marker endpoints do not prove neuronal survival in sporadic PD.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID37873141. Subclaims: SC2, SC5.

### [21] Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.

**Shows:** USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.

**Does not show:** A protein-triggered model supports a modifiable downstream quality-control contribution; it does not establish mitochondrial-first onset in humans.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [22] Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models.

**Shows:** Encapsulated mitochondrial transfer rescues bioenergetics in patient cells and phenotypes in mitochondrial-disease mice, with neuronal/motor rescue in a PD model.

**Does not show:** Organelle delivery is pleiotropic and induced-model specific; no human PD trajectory is established; linked correction details are unexamined.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID42140184. Subclaims: SC2, SC5.

### [23] Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice.

**Shows:** Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.

**Does not show:** The demonstrated phenotype is immune-context-dependent axonal dysfunction, not established nigral cell death or unconditional respiratory-loss sufficiency.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [24] Rotenone, paraquat, and Parkinson's disease.

**Shows:** A nested agricultural case-control study links rotenone/paraquat exposure groups to diagnosed PD.

**Does not show:** Recall, co-exposures and non-mitochondrial toxic actions prevent a selective instrument or proof that age-related respiration failure mediates onset.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [25] BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease.

**Shows:** BCKDK loss destabilizes complex I and promotes alpha-synuclein pathology; restoring BCKDK rescues respiration and partly restores patient-derived cell markers.

**Does not show:** Stress-conditioned cellular rescue and postmortem associations do not establish spontaneous in-vivo neuronal loss or mitochondrial primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [26] Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study.

**Shows:** Two homozygous PINK1 Q456X relatives develop early PD with loss of kinase/Parkin-substrate function; heterozygous carriers remain unaffected.

**Does not show:** Familial gene causality and peripheral fibroblast assays do not isolate bioenergetics from immune/quality-control actions or explain sporadic late-life disease.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [27] Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.

**Shows:** Whole-mitochondrial sequencing of disease/control brains finds no major disease association for rare inherited or heteroplasmic point variants, with some copy-number differences.

**Does not show:** Bulk tissue may miss single-cell deletion lesions; a point-mutation null cannot exclude deletion/compartment effects; linked erratum details unexamined.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID28228164. Subclaims: SC1, SC4, SC5.

### [28] Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

**Shows:** PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.

**Does not show:** Mutant huntingtin represses PGC-1alpha upstream; global biogenesis loss and overexpression rescue support contribution within genetic HD, not sporadic mitochondrial initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [29] Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

**Shows:** HD mice show thermoregulatory, mitochondrial and PGC-1alpha target abnormalities; exogenous PGC-1alpha protects striatal cells from a mitochondrial toxin.

**Does not show:** Brown-fat and toxin phenotypes do not independently prove endogenous striatal necessity or an etiological apex; huntingtin is the defined initiating mutation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [30] Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.

**Shows:** Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice.

**Does not show:** A pan-PPAR agonist is pleiotropic; benefits under mutant HTT do not identify biogenesis alone or reverse genetic upstream order.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [31] Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites.

**Shows:** Original Results show reduced ATP and spare glycolytic capacity with largely retained respiratory reserve; late glycolytic metabolites improve ATP and mutant-HTT neuron viability.

**Does not show:** One long-repeat line has reduced maximal respiration; rescue in transfected mouse neurons differs from human-cell ATP rescue; small donor panels and artificial cultures limit generalization.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph11, 1:Results:paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [32] Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients.

**Shows:** The common mtDNA deletion is lower in two HD regions and unchanged in caudate, with similar respiratory-polypeptide staining.

**Does not show:** Bulk gliosis can replace deletion-rich neurons and obscure vulnerability; this does not exclude every mitochondrial lesion.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [33] Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients.

**Shows:** HD platelet-mtDNA cybrids resemble control cybrids in respiration, oxidative stress and calcium assays.

**Does not show:** The model excludes nuclear mutant HTT and tissue-specific effects; it constrains mitochondrial inheritance claims rather than all HD metabolic mechanisms.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [34] Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.

**Shows:** Isolated synaptic/non-synaptic mitochondria and R6/2 striatal cultures show retained respiration, ATP and calcium handling.

**Does not show:** Age, preparation and fragment-model conditions bound this negative result; isolated organelles can omit intact-neuron interactions.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [35] Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.

**Shows:** Affected HD-model brain tissue has increased glycolytic flux and ATP with altered enzyme activity and a fitted metabolic model.

**Does not show:** Whole-tissue averages and partially predictive kinetic modelling do not establish neuronal ATP sufficiency or validate the proposed enzyme-channeling explanation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [36] Mutant huntingtin does not cross the mitochondrial outer membrane.

**Shows:** Protease/alkali localization and respiratory assays place mutant HTT outside the mitochondrial outer membrane with no TIM23 import deficit in the examined preparations.

**Does not show:** This challenges a specific import route, not every HTT-mitochondrial interaction or stage of HD; postmortem and isolation constraints persist.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [37] A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.

**Shows:** Brain-specific PPARGC1A isoforms and regional haplotypes associate with HD onset age and show neuronal promoter activity.

**Does not show:** Association of a broad regulatory locus is not a selective causal instrument for mitochondrial biogenesis or proof of primary initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

### [38] Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.

**Shows:** Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.

**Does not show:** A-beta acts upstream of pore stress; lifelong knockout and model cognition do not establish sporadic onset or clinical disease modification.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [39] New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.

**Shows:** Ebselen/CypD blockade improves bioenergetics in sporadic AD cybrids and cognition, synaptic/inflammatory phenotypes in AD mice.

**Does not show:** Ebselen has additional redox actions and induced-model benefits; no clinical trajectory or unique upstream cause is shown.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [40] Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease.

**Shows:** Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.

**Does not show:** The rescue starts at four weeks, before disease, rather than reversing established dementia; 3xTg mutations and a roughly twofold transgene are not sporadic etiological proof.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph3, 1:Results:paragraph7, 1:Results:paragraph9, 1:Results:paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [41] Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline.

**Shows:** Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.

**Does not show:** A severe engineered efflux lesion and indications of death are not normal aging or proof of human universal initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [42] Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression.

**Shows:** Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.

**Does not show:** Protection in a familial transgenic setting supports calcium dependence; the corresponding preprint is the same study, not independent replication or human disease modification.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID37904949. Subclaims: SC2, SC5.

### [43] Cybrids in Alzheimer's disease: a cellular model of the disease?

**Shows:** AD platelet-mtDNA cybrids display reduced COX activity and increased ROS/scavenging activity in a standardized nuclear background.

**Does not show:** Transfer into mtDNA-depleted tumor cells is artificial; the abstract infers mutations without identifying a causal variant or establishing prediagnostic neuronal onset.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [44] Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways.

**Shows:** AD cybrids show mitochondrial depolarization, caspase/A-beta changes and pharmacological modulation of A-beta secretion.

**Does not show:** Selected cell lines and broad antioxidants/caspase inhibitors cannot establish primary in-vivo disease onset or unique mtDNA causality.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [45] Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease.

**Shows:** MCI platelet-mtDNA cybrids show COX and oxidative-stress deficits and AD cybrids contain increased mitochondrial A-beta.

**Does not show:** MCI is not pathology-free or necessarily pre-amyloid; cross-sectional transfer cannot prove mitochondrial change precedes proteinopathy in donors.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [46] Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease.

**Shows:** AD platelet and brain-synaptosome mtDNA restores respiration similarly to age-matched controls in HeLa cybrids.

**Does not show:** Different nuclear background and cell selection could alter sensitivity; the null contradicts universal transferable respiratory failure without excluding brain-specific interactions.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [47] Mitochondrial DNA Manipulations Affect Tau Oligomerization.

**Shows:** Acute/chronic mtDNA depletion and AD cybrid transfer increase tau oligomers in SH-SY5Y cells.

**Does not show:** Ethidium-bromide stress, rho-zero adaptation and common transformed-cell platforms share failure modes; no human onset or neuronal fate is demonstrated.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [48] Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease.

**Shows:** MCI/AD donor-mtDNA cybrids show altered tau phosphorylation and proteomes, correlating with donor plasma, cognition and morphology.

**Does not show:** Constructed cells and cross-sectional donor correlations do not track causal onset or selective mitochondrial disease prevention.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [49] Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function.

**Shows:** Induced familial PS1 mutations disturb mitochondrial/MAM physiology; ATL2 lowering corrects abnormal contacts in cells.

**Does not show:** Genetically determined protein changes are upstream in this design; morphology rescue and familial cell lines do not establish mitochondrial primacy in sporadic AD.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [50] ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes.

**Shows:** Isogenic APOE4 astrocytes show lysosomal cholesterol retention and respiratory defects rescued by cholesterol depletion.

**Does not show:** The cellular pathway is genotype/lysosome-led; no human neuronal trajectory or exclusive respiration-mediated risk is established.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [51] TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models.

**Shows:** Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.

**Does not show:** A myeloid inflammatory intervention is not selective neuronal mitochondrial restoration, and amyloid-linked effects do not identify the initial sporadic event.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [52] Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis.

**Shows:** CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.

**Does not show:** This is an engaged genetic dissociation between soma preservation and fatal paralysis; it bounds the pore mechanism, not every mitochondrial process or human sporadic ALS.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [53] The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice.

**Shows:** CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.

**Does not show:** Later multi-mutant experiments fail to reproduce disease-trajectory benefit despite engagement; model/background discrepancies remain unresolved.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [54] TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS.

**Shows:** TDP-43 releases mitochondrial DNA and cGAS/STING suppression prevents downstream inflammatory signalling in cells and mutant mice.

**Does not show:** TDP-43 is upstream experimentally; cytokine suppression and patient cGAMP do not establish mitochondrial-first disease or restored human function.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [55] Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis.

**Shows:** Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.

**Does not show:** Engineered sufficiency does not identify spontaneous sALS initiation; correction details unexamined and reported human-deficiency prevalence is not independently audited here.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID40119207. Subclaims: SC2, SC5.

### [56] Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS.

**Shows:** Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.

**Does not show:** This places protein toxicity before mitochondrial impairment and tests a familial interaction, not a universal mitochondrial initiator.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [57] Miro1 deficiency in amyotrophic lateral sclerosis.

**Shows:** ALS tissue/models show reduced Miro1 and glutamate challenge lowers Miro1 in motor neurons.

**Does not show:** Expression and excitotoxic challenge support a downstream transport route; selective transport rescue with survival is absent from the examined abstract.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [58] Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

**Shows:** A prospective randomized trial using prior-study-defined early-ALS eligibility shows less 24-week ALSFRS-R decline with edaravone.

**Does not show:** This establishes a restricted antioxidant clinical effect, not specific mitochondrial restoration or upstream cause; broad efficacy cannot be inferred from the selected cohort.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [59] Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.

**Shows:** A propensity-matched German long-term cohort finds no ALS progression, ventilation or survival advantage with edaravone, including eligibility-defined strata.

**Does not show:** Treatment selection, residual confounding and exposure/completer selection prevent equivalence to randomized rejection; linked correction details unexamined.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID35696158. Subclaims: SC6.

### [60] Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

**Shows:** EMPOWER finds no dexpramipexole benefit on prespecified combined function/survival or separate efficacy endpoints.

**Does not show:** A drug-regimen null with uncertain cellular target engagement cannot falsify every mitochondrial driver; an author-name correction is retained.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC6.

### [61] A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.

**Shows:** Olesoxime does not improve 18-month survival or sustained functional endpoints in riluzole-treated ALS.

**Does not show:** Blood levels do not establish mitochondrial occupancy in target motor neurons; one transient secondary signal is not sustained disease modification.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [62] Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

**Shows:** An adaptive CoQ10 ALS trial finds insufficient promise to proceed, with null secondary outcomes and sensitivity-dependent futility analyses.

**Does not show:** A futility design is not a conventional superiority trial and does not establish adequate CNS mitochondrial engagement or mechanism absence.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [63] Dexpramipexole is ineffective in two models of ALS related neurodegeneration.

**Shows:** Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure.

**Does not show:** Negative compound performance constrains translational rationale rather than every mitochondrial mechanism; a marginal single cellular indicator is retained.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC6.

### [64] A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

**Shows:** High-dose CoQ10 in early PD reaches prespecified futility without clinical UPDRS benefit.

**Does not show:** This treatment failure does not establish adequate neuronal engagement, timing or complete disproof of bioenergetic contribution.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [65] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

**Shows:** Long-term NET-PD creatine randomization is stopped for futility on a composite clinical progression outcome.

**Does not show:** Energy buffering is broad and clinical treatment begins after diagnosis; neuronal mitochondrial correction is not demonstrated by this outcome.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [66] Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.

**Shows:** STEADY-PD III isradipine shows no three-year clinical progression benefit or secondary benefit.

**Does not show:** The original abstract explicitly allows insufficient neuroprotective calcium-channel engagement; a universal engaged-mechanism null would overstate it.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [67] A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

**Shows:** Original UDCA Methods define safety as primary; Results show midbrain MRS energetic changes and a small sensor-gait signal, with null UPDRS group contrasts.

**Does not show:** Thirty-one were randomized; MRS/gait subsets are smaller, secondary analyses unpowered and unadjusted for multiplicity; no established disease-modifying trajectory or cell-specific adequate engagement.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [68] The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.

**Shows:** NADPARK increases brain NAD variably and alters metabolic/inflammatory measures after 30 days.

**Does not show:** Phase-I biomarker engagement and responder-associated clinical change do not establish progression; response-defined subsets cannot prospectively define scope.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [69] NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.

**Shows:** NR-SAFE supports short-term high-dose tolerability and blood NAD elevation in 20 patients.

**Does not show:** Clinical change covaries with time since levodopa; four weeks and blood metabolites cannot establish mitochondrial disease modification.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.

### [70] A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

**Shows:** 2CARE high-dose CoQ10 in genetic HD is stopped for futility without functional-capacity or survival benefit.

**Does not show:** The initiating HTT mutation is distinct from mitochondrial support; no adequate neuronal biochemical engagement is established by the null clinical outcome.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6.